On Invalid Date, Neogenomics (NASDAQ: NEO) reported Q2 2023 earnings per share (EPS) of -$0.19, up 32.14% year over year. Total Neogenomics earnings for the quarter were -$24.33 million. In the same quarter last year, Neogenomics's earnings per share (EPS) was -$0.28.
On Invalid Date, Neogenomics (NASDAQ: NEO) reported Q2 2023 revenue of $146.92 million up 17.47% year over year. In the same quarter last year, Neogenomics's revenue was $125.07 million.
What was NEO's revenue growth in the past year?
As of Q3 2023, Neogenomics's revenue has grown 12.73% year over year. This is 10.82 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 1.91%. Neogenomics's revenue in the past year totalled $551.62 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.